Everything below concerns LKKTETQ. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
In the lateral hypothalamus, leptin inhibits hunger by counteracting the effects of neuropeptide Y, a potent hunger promoter secreted by cells in the gut and in the hypothalamus counteracting the effects of anandamide, another potent hunger promoter that binds to the same receptors as THC In the medial hypothalamus, leptin stimulates satiety by promoting the synthesis of α-MSH, a hunger suppressant Thus, a lesion in the lateral hypothalamus causes anorexia (due to a lack of hunger signals) and a lesion in the medial hypothalamus causes excessive hunger (due to a lack of satiety signals). This appetite inhibition is long-term, in contrast to the rapid inhibition of hunger by cholecystokinin (CCK) and the slower suppression of hunger between meals mediated by PYY3-36. The absence of leptin (or its receptor) leads to uncontrolled hunger and resulting obesity. Fasting or following a very-low-calorie diet lowers leptin levels. Leptin levels change more when food intake decreases than when it increases. The dynamics of leptin due to an acute change in energy balance may be related to appetite and eventually, to food intake rather than fat stores.
His tenure as president was taken up largely by fundraising activities, and involved travelling around various campuses in South Africa to recruit students and deepen the movement's ideological base. Some of these students censured him for abandoning NUSAS' multi-racial approach; others disapproved of SASO's decision to allow Indian and Coloured students to be members. Biko stepped down from the presidency after a year, insisting that it was necessary for a new leadership to emerge and thus avoid any cult of personality forming around him. SASO decided after a debate to remain non-affiliated with NUSAS, but would nevertheless recognise the larger organisation as the national student body. One of SASO's founding resolutions was to send a representative to each NUSAS conference. In 1970 SASO withdrew its recognition of NUSAS, accusing it of attempting to hinder SASO's growth on various campuses. SASO's split from NUSAS was a traumatic experience for many white liberal youth who had committed themselves to the idea of a multi-racial organisation and felt that their attempts were being rebuffed. The NUSAS leadership regretted the split, but largely refrained from criticising SASO. The government – which regarded multi-racial liberalism as a threat and had banned multi-racial political parties in 1968 – was pleased with SASO's emergence, regarding it as a victory of apartheid thinking.
== Mechanism == Subunit vaccines contain fragments of the pathogen, such as protein or polysaccharide, whose combinations are carefully selected to induce a strong and effective immune response. Because the immune system interacts with the pathogen in a limited way, the risk of side effects is minimal. An effective vaccine would elicit the immune response to the antigens and form immunological memory that allows quick recognition of the pathogens and quick response to future infections. A drawback is that the specific antigens used in a subunit vaccine may lack pathogen-associated molecular patterns which are common to a class of pathogen. These molecular structures may be used by immune cells for danger recognition, so without them, the immune response may be weaker. Another drawback is that the antigens do not infect cells, so the immune response to the subunit vaccines may only be antibody-mediated, not cell-mediated, and as a result, is weaker than those elicited by other types of vaccines. To increase immune response, adjuvants may be used with the subunit vaccines, or booster doses may be required.
On May 30, 2024, Trump was found guilty by a jury of all 34 felony counts in The People of the State of New York v. Donald J. Trump. The jury found that Trump falsified business records relating to hush money payments made to pornographic film star Stormy Daniels to ensure her silence about a sexual encounter between them. This conviction made Trump the first former U.S. president to be convicted of a crime. On January 10, 2025, Trump was given a no-penalty sentence known as an unconditional discharge. Trump faced other criminal charges as well. In United States of America v. Donald J. Trump, Trump faced four criminal counts for his alleged role in attempting to overturn the 2020 United States presidential election and involvement in the January 6 United States Capitol attack; the case was dismissed following Trump's re-election in November 2024. In The State of Georgia v. Donald J. Trump, et al., Trump was charged with eight criminal counts for his alleged attempts to overturn the results of the 2020 United States presidential election in Georgia. District Attorney Fani Willis was disqualified from prosecuting the case; Willis has appealed that decision. In United States of America v. Donald J. Trump, Waltine Nauta, and Carlos De Oliveira, Trump faced 40 criminal counts relating to his hoarding of classified documents and alleged obstruction of efforts to retrieve them; the case was dismissed in July 2024. On May 9, 2023, in E. Jean Carroll v. Donald J.
Sources: en.wikipedia.org
Usually, an enzyme molecule has only one active site, and the active site fits with one specific type of substrate. An active site contains a binding site that binds the substrate and orients it for catalysis. The orientation of the substrate and the close proximity between it and the active site is so important that in some cases the enzyme can still function properly even though all other parts are mutated and lose function. Initially, the interaction between the active site and the substrate is non-covalent and transient. There are four important types of interaction that hold the substrate in a defined orientation and form an enzyme-substrate complex (ES complex): hydrogen bonds, van der Waals interactions, hydrophobic interactions and electrostatic force interactions. The charge distribution on the substrate and active site must be complementary, which means all positive and negative charges must be cancelled out. Otherwise, there will be a repulsive force pushing them apart. The active site usually contains non-polar amino acids, although sometimes polar amino acids may also occur. The binding of substrate to the binding site requires at least three contact points in order to achieve stereo-, regio-, and enantioselectivity. For example, alcohol dehydrogenase which catalyses the transfer of a hydride ion from ethanol to NAD+ interacts with the substrate methyl group, hydroxyl group and the pro-(R) hydrogen that will be abstracted during the reaction.
=== Biosignaling === For isopeptide bonds linking one protein to another for the purpose of signal transduction, the literature is dominated by ubiquitin and other similar proteins. Ubiquitin and its related proteins (SUMO, Atg8, Atg12, etc.) all tend to follow relatively the same protein ligation pathway. The process of protein ligation by ubiquitin and ubiquitin-like proteins has three main steps. In the initial step, the specific activating protein (E1 or E1-like protein) activates Ubiquitin by adenylating it with ATP. Then the adenylated Ubiquitin can be transferred to a conserved cysteine using a thioester bond which is between the carboxyl group of the C-terminal glycine of the ubiquitin and the sulfur of the E1 cysteine. The activating E1 enzyme then binds with and transfers the Ubiquitin to the next tier, the E2 enzyme which accepts the protein and once again forms a thioester with a conserved bond. The E2 acts to certain degree as an intermediary which then binds to E3 enzyme ligase for the final tier, which leads to the eventual transfer of the ubiquitin or ubiquitin related protein to a lysine site on the targeted protein, or more commonly for ubiquitin, onto ubiquitin itself to form chains of said protein. However, in final tier, there is also a divergence, in that depending on the type of E3 ligase, it may not actually be causing the conjugation.
== Exocrine cell type == Morphology is what identifies ductal cells. However, there is barely anything to differentiate pancreatic ductal cells from other bodily ductal cells. There is still a lot unknown about these ductal cells. Their molecular identity still needs to be improved; more knowledge is necessary regarding stage-specific markers and the regulators of ductal cell development. It recently was discovered that the ducts start as separate microlumens in a stratified epithelium that expand, attach, and resolve to form the pancreatic ducts. These cells work with intercalating ducts that link to distinct acini and are within the larger ducts in the two core pancreatic ducts (dorsal and ventral duct) that drain into the intestine. Ductal cells are exocrine, but they are more like endocrine cells when developing. A recent lineage analysis showed that ductal cells came directly from bipotent precursor cells and have the possibility of creating either ductal or endocrine cells. Meanwhile, mature ducts have a restricted ability to transdifferentiate to other types of cells, even when the pancreas is injured.
Joy Osmanski as Paula Brooks / Tigress (season 3; recurring season 1; guest season 2):A member of the ISA who hunts the world's most dangerous humans. She is a gym teacher at Blue Valley High, the wife of "Crusher" Crock, and mother of Artemis Crock. In the second season, she breaks out of prison twice. In the third and final season, she moves in next door to the Whitmore-Dugans. Joel McHale as Sylvester Pemberton / Starman and Gerard Shugel / Ultra-Humanite (season 3; guest season 1; recurring season 2):A member of the original JSA who used an anti gravity Cosmic Staff invented by scientist Ted Knight that Courtney later finds. In the present, Ultra-Humanite forms an alliance with Icicle and Dragon King before transplanting his brain into Sylvester Pemberton's body in order to manipulate Stargirl and her JSA, and Dragon King's brain into Ultra-Humanite's albino gorilla body for him to "defeat" as Starman alongside Jordan's son before intending to run for president as a mouthpiece for Icicle to spread his ideals.
CosMc's (, KAHZ-miks) was an American concept fast food restaurant and spinoff brand by McDonald's. Its menu focused on hot and cold speciality drinks. It launched on December 7, 2023, with a drive-thru only location in the Chicago suburb of Bolingbrook, Illinois. Nine locations were planned to open in Texas in 2024. CosMc's offered McCafe products, some of which are also available at McDonald's locations, alongside exclusive drinks and food.
Sources: en.wikipedia.org
In Australia, New Zealand, and the United States, it is considered an analog of other illegal drugs and can be controlled under laws similar to the US Federal Analog Act. In September 2011, the US temporarily classified mephedrone as a Schedule I drug, with the classification taking effect in October 2011. This was made permanent in July 2012 with the passage of the Synthetic Drug Abuse Prevention Act (SDAPA).
237Np decays via the neptunium series, which terminates with thallium-205, which is stable, unlike most other actinides, which decay to stable isotopes of lead. Until the discovery of its alpha decay (with an extremely long half-life), the series was thought to end with bismuth-209. In 2002, 237Np was shown to be capable of sustaining a chain reaction with fast neutrons, as in a nuclear weapon, with a critical mass of around 60 kg. However, it has a low probability of fission on bombardment with thermal neutrons, which makes it unsuitable as a fuel for light water nuclear power plants (as opposed to fast reactor or accelerator-driven systems, for example).
=== Pharmacoperones === Current research is looking into pharmacoperones, or chemical chaparones that promote the shuttling of mature Gonadotropin-releasing hormone receptor (GNRHR) protein to the cell surface, leading to a functional protein. Gonadotropin-releasing hormone receptor function has been shown to be deleteriously effected by point mutations in its gene. Some of these mutations, when expressed, cause the receptor to remain in the cytosol. An approach to rescue receptor function utilizes pharmacoperones or molecular chaperones, which are typically small molecules that rescue misfolded proteins to the cell surface. These interact with the receptor to restore cognate receptor function devoid of antagonist or agonist activity. This approach, when effective, should increase therapeutic reach. Pharmacoperones have been identified that restore function of Gonadotropin-releasing hormone receptor.
== See also == Alpha toxin Pathology Lysosomal acid lipase deficiency Peripheral membrane proteins Phospholipase A Phospholipase C Triglyceride lipase Phospholipase A2 Outer membrane phospholipase A1 Patatin-like phospholipase
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.